Skip to main content
. 2021 Jun;27(6):1588–1597. doi: 10.3201/eid2706.203206

Table 1. Patient demographics and clinical characteristics of children infected with macrolide-sensitive and macrolide-resistant strains of Mycoplasma pneumoniae, Ohio, USA, 2015–2019*.

Characteristic MRMp, n = 12 MSMp, n = 332 p value
Sex 0.9046
M 7 (55) 175 (53)
F
5 (45)
157 (47)

Year 0.6508
2015 4 (33) 146 (44)
2016 1 (8) 51 (15)
2017 2 (17) 52 (16)
2018 5 (42) 73 (22)
2019
0
10 (3)

Age, y, mean (SD)
9.13 (3.74)
8.73 (4.62)
0.7683
Previous visits
Any previous visits 8 (67) 188 (57) 0.4901
No. previous visits, median (IQR)
1.5 (1–2)
1 (1–2)
0.3491
Underlying conditions 6 (50) 139 (42) 0.5752
Chronic immunosuppression 1 (8) 5 (2) 0.1392
Up to date in vaccines
12 (100)
316 (97)
>0.9999
Inpatient 6 (50) 130 (39) 0.551
Median duration of hospitalization, d (IQR)
8 (6–10)
2 (1.5–3)
0.0132
PICU 3 (25) 21 (6) 0.0433
Median duration of PICU stay, d (IQR)
2 (1–8)
2 (1.5–5)
0.8596
Hypoxemia 3 (25) 73 (23) >0.9999
Median duration of O2 support, d (IQR) 4 (1–8.5) 1 (0.5–2) 0.1302
Mechanical ventilation
1 (33)
6 (8)
0.2487
Median duration of symptoms, d (IQR)
7 (6.5–13)
7 (5–10)
0.3324
Fever 11 (92) 271 (81) 0.7024
Median duration of fever, d (IQR) 4 (2–7) 4 (2–7) 0.984
Median maximum temperature, °C (IQR)
38.4 (38.1–39.4)
39.1 (38.4–39.7)
0.0415
Fatigue 5 (42) 91 (27) 0.3298
Decreased appetite/oral food intake 4 (33) 125 (38) >0.9999
Decreased urine output 0 22 (7) >0.9999
Cough 12 (100) 320 (96) >0.9999
Shortness of breath/respiratory distress 5 (42) 91 (27) 0.3268
Sore throat 0 67 (20) 0.1332
CNS manifestation 2 (17) 10 (3) 0.0607
Nausea/vomiting 1 (8) 55 (17) 0.6987
Diarrhea 1 (8) 30 (9) >0.9999
Rash 0 25 (7.5) >0.9999

*Values are no. (%) except as indicated. Bold type indicates statistical significance. CNS, central nervous system; IQR, interquartile range; MRMp, macrolide-resistant Mycoplasma pneumoniae; MSMp, macrolide-sensitive Mycoplasma pneumoniae; PICU, pediatric intensive care unit.